A detailed history of Barclays PLC transactions in Lyra Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 63,303 shares of LYRA stock, worth $11,394. This represents 0.0% of its overall portfolio holdings.

Number of Shares
63,303
Previous 63,303 -0.0%
Holding current value
$11,394
Previous $16,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$0.24 - $0.34 $11,207 - $15,877
46,699 Added 281.25%
63,303 $16,000
Q2 2024

Aug 14, 2024

SELL
$0.26 - $6.25 $4,215 - $101,331
-16,213 Reduced 49.4%
16,604 $4,000
Q4 2023

Feb 15, 2024

BUY
$2.82 - $5.24 $92,543 - $171,961
32,817 New
32,817 $172,000

Others Institutions Holding LYRA

About Lyra Therapeutics, Inc.


  • Ticker LYRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,826,400
  • Market Cap $5.73M
  • Description
  • Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...
More about LYRA
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.